Paclitaxel and carboplatin (TC) chemotherapy is an effective and well-tolerated regimen against advanced endometrial cancer. Organic anion transporting polypeptide 1B3 (OATP1B3) and copper transporter 1 (CTR1) are critical for the uptake of paclitaxel and carboplatin, respectively. This study aimed to address the prognostic impact of OATP1B3 and CTR1 in endometrial cancer patients treated with adjuvant TC chemotherapy. We immunohistochemically evaluated the expressions of OATP1B3 and CTR1 in 47 stage III endometrial cancers. The high expression levels of OATP1B3 were significantly correlated with type I tumor (P = 0.0005). In univariate analysis, high expression levels of OATP1B3 (P = 0.047) and CTR1 (P = 0.009) were significantly associated with longer disease-free survival (DFS) and longer overall survival (OS), respectively. The patients with tumors showing high expression levels of at least one of OATP1B3 and CTR1 had potentially longer DFS (P = 0.058) and significantly longer OS (P = 0.003) in the univariate analysis. Combined OATP1B3/CTR1 expression was the sole independent prognostic factor for longer OS in the multivariate analysis (P = 0.013). Our findings suggest that combined OATP1B3/CTR1 expression is a possible predictive/prognostic factor for a good outcome in stage III endometrial cancer patients treated with adjuvant TC chemotherapy.
Endometrial cancer is one of the most common malignancies of the female genital system (19) . For patients with primary advanced or recurrent endometrial cancer, chemotherapy is the standard treatment option (4) . Recently, paclitaxel and carboplatin (TC) chemotherapy has begun to be widely applied for the treatment of endometrial cancer, based on its initially reported effectiveness and high tolerability (14, 16, 23, 25) . The cytotoxicity of anticancer drugs is directly related to how much drug enters the cell, and the most commonly acquired type of resistance is reduced drug accumulation (5) . Uptake mechanisms into tumor cells may be even more important than efflux transporters for the efficacy of anticancer drugs because they are determinants of intracellular drug concentration (5) . Organic anion transporting polypeptides (OATPs; with pelvic and/or para-aortic lymphadenectomy. The histologic specimens were fixed in 10% formalin and were routinely processed for paraffin embedding. The paraffin-embedded specimens were sectioned at 4 μm thickness, and were stained with hematoxylin and eosin and by immunoperoxidase procedures. The histology included 18 type I tumors (grades 1 and 2 endometrioid carcinomas) and 29 type II tumors (13 grade 3 endometrioid carcinomas, 2 serous carcinomas, 1 clear cell carcinoma, 7 carcinosarcomas, 1 undifferentiated carcinoma, and 5 mixed-type carcinomas) (2) . The histologic grade of the endometrioid carcinomas was determined according to the FIGO system. The patients underwent 6 cycles of a TC regimen of paclitaxel 175 mg/m 2 and carboplatin area under the curve of 5 mg/mL/min as postoperative adjuvant therapy. No other anticancer drug and radiation were given. All the patients were followed up with laboratory examinations including routine peripheral blood cell counts, transvaginal and abdominopelvic ultrasonography, and radiological examination. The follow-up period for survivors ranged from 8 to 92 months (median, 47 months). All the patients provided written informed consent before the treatment commenced. The study was approved by the local ethics committee.
Immunostaining. The sections were deparaffinized with xylene and were rehydrated with a graduated series of ethanol solutions (100% ethanol followed by 95% and then 80% ethanol). Endogenous peroxidase was blocked by incubating the sections in 0.3% hydrogen peroxide in methanol for 30 min. The antigenicities of OATP1B3 and CTR1 were retrieved by heat-induced antigen retrieval (HIAR) and proteaseinduced antigen retrieval (PIAR) methods, respectively. HIAR was applied using a pressure cooker (T-fal, Rumily, France) for 10 min at 120°C in an optimal soaking solution (0.01 mol/L citrate buffer, pH 7.0). After pressure cooking, the sections were left at room temperature (RT) to cool in the soaking solution for 30 min. PIAR was accomplished using 0.16 U/g pronase solution (Nichirei Bioscience, Tokyo, Japan) for 4 min at RT. The sections were washed in running tap water followed by 0.01 mol/L phosphate-buffered saline (PBS; pH 7.2). After blocking with 0.25% casein in PBS (Dako, Glostrup, Denmark) for 5 min at RT, the sections were incubated for 16 h at RT with rabbit polyclonal anti-human OATP1B3 antibody (1 : 200 dilution; Sigma-Aldrich, MO, USA) or rabbit polyclonal antihuman CTR1 antibody (1 : 100 dilution; Abnova, encoded by SLCO/SLC21 genes) transport a variety of pharmaceuticals into cells including anticancer agents, antibiotics, hydroxymethylglutaryl-CoAreductase inhibitors (statins), and cardiac glycosides (6, 20) . OATPs have also been shown to contribute to systemic variation in anticancer drug treatments. For instance, OATP1B3, also referred to as SLCO1B3 or SLC21A8, was initially identified as a high-affinity transporter of paclitaxel (21) . OATP1B3 is exclusively expressed in pericentral hepatocytes in the liver (20) . Copper transporter 1 (CTR1), also referred to as SLC31A1, is the major copper influx transporter. According to a prior immunohistochemical study, in normal human tissues, CTR1 is expressed in a subset of tissues and cell types including mammary ductal and lobular cells, renal distal tubular cells, endometrial glandular epithelial cells, splenic lymphoid nodules, and neuroendocrine cells of various organs (9) . CTR1 has been convincingly demonstrated to control tumor cell accumulation and cytotoxic effect of platinum drugs, cisplatin and carboplatin (7, 22) , and genetic knockout of CTR1 renders the cells resistant to cisplatin in vivo (11) . These preclinical studies suggest that intratumoral expressions of OATP1B3 and CTR1 may have a predictive/prognostic value for cancer patients treated with TC chemotherapy. However, the role of drug transporters in endometrial cancer treatment is unknown. The aims of this study were to determine the relationship between the outcome of endometrial cancer patients after surgery followed by adjuvant TC chemotherapy and the expression levels of OATP1B3 and CTR1 in tumors, as assessed by immunohistochemistry, and to clarify the predictive/ prognostic values of OATP1B3 and CTR1 with regard to the patients' survival. (15) . Table 1 summarizes the clinicopathologic findings for the 47 patients. The patients ranged in age from 35 to 79 years (median, 57.0 years). All the patients underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and partial omentectomy percentage of positive tumor cells was scored as follows: 0, no positive tumor cells; 1, < 30% positive cells; 2, 30-60% positive cells; and 3, ≥ 61% positive cells. A composite score was obtained by calculating the sum of these two scores. We classified the scores of 0-3 for OATP1B3 and 0-4 for CTR1 as low expression levels and the scores of 4-6 for OATP1B3 and 5-6 for CTR1 as high expression levels. The independent scores from both investigators were consolidated into a final score. Any differences in the scores were adjudicated following discussion between the two investigators.
PATIENTS AND METHODS

Patients
Statistical analysis. The Spearman rank correlation test was applied to measure the strength of association between the expression levels of the OATP1B3 and CTR1. The Fisher' exact test was used to determine the correlation between transporter expression and patient age, tumor size, histologic type, depth of myometrial invasion, vascular invasion, cervical involvement, or FIGO substage. The disease-free survival (DFS) and overall survival (OS) rates were estimated using the KaplanMeier method, and the difference between the survival Taipei, Taiwan). The sections were then rinsed in PBS, followed by incubation with Histofine Simple Stain MAX-PO (Nichirei Bioscience) for 1 h at RT. The reaction products were visualized with a diaminobenzidine solution (Dako). Subsequently, the sections were rinsed, counterstained with hematoxylin, dehydrated through graded alcohol and xylene, and finally coverslipped. The sections of liver and kidney were used as positive staining controls for OATP1B3 and CTR1, respectively. Negative controls were provided by omitting the primary antibodies.
Scoring of immunostaining.
The stained sections were assessed by two investigators (N.O. and S.K.) who were blined to clinical characteristics and outcome data. The staining was regarded as positive when the tumor cells showed membranous positivity: cytoplasmic staining was ignored. The semiquantitative assessment of the OATP1B3 and CTR1 expressions was performed by scoring the staining intensity and percentage of stained tumor cells. Briefly, the staining intensity was assigned a score from 0 to 3 as follows: 0, no staining; 1, weakly positive; 2, moderately positive; and 3, strongly positive. The Correlation between the OATP1B3 and CTR1 expression levels and the patients' clinicopathologic characteristics Table 1 shows the expression levels of OATP1B3 and CTR1 and the patients' clinicopathologic parameters. A high expression level of OATP1B3 was curves was compared by the log-rank test. DFS was defined as the time from the date of surgery to the date of first recurrence. The exact date of recurrence was defined as the date when apparent tumors were detected by ultrasonographic or radiological examination. OS was calculated from the date of surgery to the date of death. The data on the survivors were censored at the last follow-up. All variables with a P value less than 0.50 in the log-rank test were included in the Cox regression model for multivariate analysis to assess the independent prognostic factors. Differences with P < 0.05 were considered significant. These analyses were conducted with a free statistical software EZR (Easy R) on R commander version 2.13.0 (Saitama Medical Center, Jichi Medical University, Saitama, Japan).
RESULTS
Expression of OATP1B3 and CTR1
The representative staining patterns of OATP1B3 and CTR1 in the endometrial cancer tissues are shown in Fig. 1 . High expression levels of OATP1B3 
Association of the OATP1B3 and CTR1 expression levels with the patients' outcome
As of the last follow-up, 17 patients (36%) experienced tumor recurrence, 12 (26%) of whom died of the disease. Thirty-five patients were still alive at the last follow-up visit. Table 2 indicates the results of the univariate analysis of prognostic factors for DFS and OS. The patients with type I tumors showed significantly longer DFS than the patients with type II tumors (P = 0.034). Cervical involvement was significantly associated with shorter OS (P = 0.049). However, there was no significant association of DFS and OS with depth of myometrial invasion, vascular invasion, or FIGO substage. High expression levels of OATP1B3 were significantly associated with longer DFS (P = 0.047, with 100% 5-year DFS; Fig. 2A ) but not with OS (Fig. 2B) .
On the other hand, there was no association between CTR1 expression and DFS (Fig. 2C) , whereas the OS of the patients whose tumors showed high CTR1 expression levels was significantly longer than that of the patients whose tumors showed low CTR1 expression levels (P = 0.009): 5-year OS of CTR1-high patients was better than that of CTR1-low patients (86.7% versus 48.1%, respectively; Fig. 2D ). Because the prognosis of cancer patients treated with combination chemotherapy conceivably depends on the sum of the individual effects of each drug, we also analyzed whether combination of the expression data for OATP1B3 and CTR1 would be a better prognostic factor. Although not statistically Fig. 2F ). Table 3 indicates the results of the multivariate Cox regression analysis of prognostic factors for DFS and OS. We found combined OATP1B3/ CTR1 expression (hazard ratio, 0.21; 95% confidence interval, 0.06-0.71; P = 0.013) to be significant independent prognosticator for longer OS. However, the association between clinicopathologic risk factors (histologic type, vascular invasion, and cervical insignificant, the patients with tumors showing high expression levels of at least one of OATP1B3 and CTR1 had longer DFS than the patients whose tumors showed low OATP1B3 and CTR1 expression levels (P = 0.058; 5-year DFS 69.7 versus 46.7%, respectively; Fig. 2E ). In addition, the OS of the patients with tumors showing high expression levels of at least one of the transporters was significantly longer than that of the patients whose tumors showed low OATP1B3 and CTR1 expression levels (P = and CTR1 were observed in 7 (15%) and 30 (64%) of the 47 tumors, respectively. In accordance with our results, Pressler et al. (18) found that 13% of the 15 endometrial cancers had OATP1B3 mRNA expression. On the other hand, Holzer et al. (9) reported that no expression of CTR1 was observed in any of the 11 endometrial cancers examined using tissue microarrays; a smaller case population and tumor heterogeneity may have led to decreased sensitivity.
The present study showed that a high expression level of OATP1B3 was related to a type I histology (low-grade endometrioid carcinoma). This might be explained by the following considerations; it is known that the type I tumor is associated with estrogen exposure because it occurs predominantly in premenopausal or perimenopausal women (2, 17) . Indeed, it has been reported that serum levels of estrone, estrone sulfate, and estradiol are significantly increased in patients with type I tumors as compared with healthy or type II tumor-bearing patients (1) . Moreover, an in vitro study has suggested that OATP1B3 is one of the transporters contributing to the supply of estrone sulfate to estrogen-dependent breast cancer cells (13) . The univariate log-rank analysis showed that high OATP1B3 expression and type I histology were significantly associated with longer DFS. This similarity most likely results from the correlation between OATP1B3 expression level and histologic type.
We also found that a high expression level of CTR1 was significantly associated with longer OS but not with longer DFS. Recently, Lee et al. (12) demonstrated that a high expression level of CTR1 mRNA was significantly associated with longer DFS in ovarian cancer patients treated with adjuvant chemotherapy by paclitaxel or docetaxel plus carboplatin. Furthermore, Chen et al. (3) reported that high expression levels of CTR1 were associated with better chemoresponse and longer DFS and OS in nonsmall cell lung cancer patients receiving platinumvolvement) and clinical outcomes did not reach statistical significance.
DISCUSSION
Anticancer agents require transporter-mediated uptake to efficiently enter cancer cells and access their intracellular targets (5) . Several studies support the idea that tumor expression of drug-uptake transporters is mechanistically and biologically relevant to the tumor chemosensitivity (10, 20) . For example, OATP1B3 has been characterized as a high-affinity paclitaxel transporter (21) . Recently, Svoboda et al.
reported that higher mRNA levels of OATP1B3 in ovarian cancer cell lines correlated with higher uptake rates for paclitaxel (24) . In addition, they demonstrated lower IC 50 values in OATP1B3-transfected ovarian cancer cells compared with cells transfected with an empty vector. CTR1 is a copper transporter that has been associated with platinum sensitivity in cancer cells. Several in vitro studies found that transfection of the CTR1 gene in small cell lung cancer and ovarian cancer cell lines markedly promoted the uptake of platinum drugs, including cisplatin and carboplatin, and increased sensitivity to their cytotoxicity (7, 22) . In addition, studies using murine embryonic fibroblasts have shown that the cells lacking CTR1 are highly resistant to platinum drugs (8, 11) . Taken together, OATP1B3 and CTR1 are the major determinants of responsiveness to the chemotherapeutic drugs paclitaxel and cisplatin, respectively. Thus, expression levels of OATP1B3 and CTR1 may be candidate biomarkers for the prediction of tumor sensitivity to TC (combined paclitaxel and carboplatin) chemotherapy.
In the present study, we immunohistochemically analyzed the expressions of OATP1B3 and CTR1 to determine their predictive/prognostic value in endometrial cancer patients treated with adjuvant TC chemotherapy. High expression levels of OATP1B3 based first-line chemotherapy. These results suggest that CTR1 expression level may have a prognostic value for predicting the treatment efficacy in cancer chemotherapy using platinum-containing regimens.
The univariate log-rank analysis showed that the DFS of the patients with tumors showing high expression levels of at least one of these transporters was potentially longer than that of the patients whose tumors showed low OATP1B3 and CTR1 expression levels. In addition, the OS of the patients with tumors showing high expression levels of at least one of the transporters was significantly longer than that of the patients whose tumors showed low OATP1B3 and CTR1 expression levels. In the multivariate Cox regression analysis, combined OATP1B3/CTR1 expression was the sole independent prognosticator for longer OS, but the association between clinicopathologic risk factors and clinical outcomes did not retain independent significance.
In conclusion, combined OATP1B3/CTR1 expression is a possible predictive/prognostic factor for a good outcome in stage III endometrial cancer patients treated with adjuvant TC chemotherapy. An immunohistochemical analysis of OATP1B3 and CTR1 expressions may serve as a tool to identify patients who might benefit from TC chemotherapy.
Having said that, the number of patients in this study is too small to reach any definitive conclusions, and large prospective studies are needed to validate our findings.
